Is breaking up big tech just another big headache?
Appetite is growing for UNFI as the company is cutting debt and surpassing consensus earnings' estimates.
Bass Pro Shops deal should boost BXG, reverse-stock split should be ugly for existing APRN shareholders, and Biglari could bounce.
FedEx's rise on bad news and Facebook's fall on the same are two examples of how it's hard to figure out when enough's enough.
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
And why the stock will recover from this hammering on the merger news.
Pensions may not be the sexiest aspect of the merger but it doesn't make them any less important.
The President voiced concerns about industry consolidation in the defense sector and the prospects for competitively priced government contracts, adding a headache for shareholders on both ends of the deal.
I am no longer as eager to sell these shares as when I discussed this merger pre-opening.
I'm not looking for this market to suddenly reverse to the downside unless it is hit with some surprise news.
United Technologies' plans to hook up with Raytheon could give UTX shares a nice technical boost.
United Technologies and Raytheon look to control the aerospace and defense industry with their mega-merger.
Our brewing Cold War over regional and global spheres of influence with China, has forced some merger activity across the aerospace and defense industry.
Whether it passes antitrust muster or not, it's a good move for UTX.
The technical action of the oil-and-gas company's shares isn't favorable as it points to further declines in its stock price.
Retailers with their own courier services and supply chains could cut out a large chunk of FedEx revenue.
Every time you see competitors trying to team up to catch PayPal it just reminds you how PayPal is the undisputed worldwide leader.
SolarCity could weigh on TSLA for some time.
The REIT that specializes in healthcare properties hit a rough patch that meant cutting its dividend, but it appears to be righting the ship.
The headlines I keep seeing talk about if Tesla becomes 'cheap enough' it might get bought.
Is the temporary license granted for U.S. exports to Huawei part of the ongoing attempt to reach a trade deal -- or is it early stages of what might end up as a protracted cold war?
Given the sidestepping of trade restrictions for the European chipmakers, they could be poised to fill the void left by larger U.S. competitors that have long been dominant in the region.
If Pinterest is pinning its hopes of profitability on e-commerce, Etsy would be an excellent choice.
Nvidia's biggest acquisition is in the hands of Chinese regulators at an inopportune time.
Aetna's additive effects on CVS's earnings might be front and center, but it isn't fully actualized just yet.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
They're cheap, have lots of cash, and/or have fairly strong brand names.
Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
A rundown of several oil companies that could soon be on the block.